According to the European Commission’s Impact Assessment of Health Research Projects1 the original 15 member states had received 34 times more health research funding under FP7 than the 12 new members2.
The difference proves considerable imbalance and substantial underfunding of research in the new member states. Even worse both participation rate and funding of new member states of Eastern Europe have dropped since FP6.
The reason of existence of Cassovia Life Sciences is to reverse this regretful trend and correct the imbalance through enabling its members to enhance their success rate in project submissions and consortia building in Horizon 2020 and other relevant framework programmes.
1. European Commission. Impact assessment of health research projects supported by DG Research and Innovation 2002–2010, http://ec.europa.eu/research/health/pdf/impact-assessment-of-health-research-projects-on-research-2002-2010_en.pdf
2. Galsworthy M. and McKee M. Europe’s ‘Horizon 2020′ science funding programme: Horizon 2020′ science funding programme: How is it shaping up? J Health Serv Res Policy (2 May 2013, accessed 11 May 2013), link